Literature DB >> 14604275

The pathophysiology of acute graft-versus-host disease.

James L M Ferrara1, Kenneth R Cooke, Takanori Teshima.   

Abstract

The pathophysiology of acute graft-versus-host disease (GVHD) is a complex process that can be conceptualized in three phases. In the first phase, high-dose chemoradiotherapy causes damage to host tissues, including a self-limited burst of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin 1. These cytokines activate host antigen-presenting cells (APCs). In the second phase, donor T-cells recognize alloantigens on host APCs. These activated T-cells then proliferate, differentiate into effector cells, and secrete cytokines, particularly interferon (IFN)-gamma. In the third phase, target cells undergo apoptosis mediated by cellular effectors (eg, donor cytotoxic T-lymphocytes) and inflammatory cytokines such as TNF-alpha. TNF-alpha secretion is amplified by stimuli such as endotoxin that leaks across damaged gastrointestinal mucosa injured by the chemoradiotherapy in the first phase. TNF-alpha and IFN-gamma cause further injury to gastrointestinal epithelium, causing more endotoxin leakage and establishing a positive inflammatory feedback loop. These events are examined in detail in the following review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604275     DOI: 10.1007/bf02983793

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  112 in total

Review 1.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.

Authors:  E Goulmy
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

Review 2.  How do cytotoxic lymphocytes kill their targets?

Authors:  S Shresta; C T Pham; D A Thomas; T A Graubert; T J Ley
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

Review 3.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.

Authors:  G R Hill; J L Ferrara
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

4.  Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation.

Authors:  S K Jackson; J Parton; R A Barnes; C H Poynton; C Fegan
Journal:  Eur J Clin Invest       Date:  1993-09       Impact factor: 4.686

5.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

6.  Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.

Authors:  C L Farrell; J V Bready; K L Rex; J N Chen; C R DiPalma; K L Whitcomb; S Yin; D C Hill; B Wiemann; C O Starnes; A M Havill; Z N Lu; S L Aukerman; G F Pierce; A Thomason; C S Potten; T R Ulich; D L Lacey
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

7.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis.

Authors:  S M Laster; J G Wood; L R Gooding
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

8.  Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  A Panoskaltsis-Mortari; D L Lacey; D A Vallera; B R Blazar
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Authors:  K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

10.  Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor.

Authors:  G F Pierce; D Yanagihara; K Klopchin; D M Danilenko; E Hsu; W C Kenney; C F Morris
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  49 in total

1.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation.

Authors:  Tatsuo Furukawa; Tori Kurasaki-Ida; Masayoshi Masuko; Nobuhiro Tsukada; Kiyoshi Okazuka; Naoko Sato; Toshio Yano; Takashi Abe; Akihito Momoi; Yasuhiko Shibasaki; Masutaka Higashimura; Kaori Karimata; Masato Moriyama; Takashi Kuroha; Jun Takizawa; Ken Toba; Miwako Narita; Ichiro Fuse; Masuhiro Takahashi; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2010-06-09       Impact factor: 2.490

3.  [Graft-versus-Host Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and classification of GvHD].

Authors:  R Travnik; M Beckers; D Wolff; E Holler; M Landthaler; S Karrer
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

4.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

5.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Authors:  Kai Sun; Danice E C Wilkins; Miriam R Anver; Thomas J Sayers; Angela Panoskaltsis-Mortari; Bruce R Blazar; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

6.  Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Authors:  Mohammad S Hossain; David L Jaye; Brian P Pollack; Alton B Farris; Malefa L Tselanyane; Ebenezer David; John D Roback; Andrew T Gewirtz; Edmund K Waller
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

7.  Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.

Authors:  Wilfried Reichardt; Christoph Dürr; Dominik von Elverfeldt; Eva Jüttner; Ulrike V Gerlach; Mayumi Yamada; Benjie Smith; Robert S Negrin; Robert Zeiser
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

8.  Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods.

Authors:  Julia S Lehman; Shahrukh K Hashmi; Hillard M Lazarus; Rokea A El-Azhary; Lawrence E Gibson; William J Hogan; Mark R Litzow; Mrinal S Patnaik; Francis Buadi; Martha Q Lacy; Surendra Dasari; Patrick Vanderboom; Alexander Meves
Journal:  J Cutan Pathol       Date:  2017-09-14       Impact factor: 1.587

9.  Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin.

Authors:  J S Lehman; S Dasari; S S Damodaran; R A El-Azhary; L E Gibson; S K Hashmi; W J Hogan; S J Kenderian; M S Patnaik; M R Litzow; H M Lazarus; A Meves
Journal:  Clin Exp Dermatol       Date:  2018-10-02       Impact factor: 3.470

10.  Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.

Authors:  Robert Zeiser; Sawsan Youssef; Jeanette Baker; Neeraja Kambham; Lawrence Steinman; Robert S Negrin
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.